Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium nucleinate and immunomodulators in NSCLC rehabilitation
NCT06209229Phase 1Completed
- Sponsor
- MIPO Clinic
- Start
- May 2022
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium nucleinate in non-small cell lung cancer (NSCLC), sponsored by MIPO Clinic. Primary endpoints: Quality of Life at 1 year, Survival Rate at 1 year and 1 more. Started May 2022; status: completed.
02
Drugs
sodium nucleinate
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06209229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06209229.